Related Experiment Video

Updated: Jun 9, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.5K

Parishin A Inhibits Oral Squamous Cell Carcinoma via the AKT/mTOR Signaling Pathway

Lei Ma1, Zhibin Liu1, Eungyung Kim2

  • 1Department of Animal Science and Biotechnology, Research Institute for Innovative Animal Science, Kyungpook National University, Daegu 37224, Republic of Korea.

Pharmaceuticals (Basel, Switzerland)
|October 26, 2024
PubMed
Abstract

Insights

Parishin A, a natural compound, effectively inhibits oral squamous cell carcinoma (OSCC) growth, migration, and invasion. This study highlights Parishin A

Area of Science:

  • Oncology
  • Natural Products Chemistry
  • Molecular Biology

Background:

  • Oral squamous cell carcinoma (OSCC) presents a significant therapeutic challenge due to its aggressive nature and limited treatment options.
  • Parishin A, a compound from *Gastrodia elata*, exhibits diverse therapeutic properties, but its role in OSCC is not yet understood.

Purpose of the Study:

  • To investigate the anti-cancer effects of Parishin A on OSCC.
  • To elucidate the underlying molecular mechanisms of Parishin A's action in OSCC.

Main Methods:

  • OSCC cell lines were treated with varying concentrations of Parishin A.
  • Cell viability, colony formation, migration, and invasion were assessed using CCK-8, agarose gel, wound healing, and Matrigel assays, respectively.
  • Protein expression of the PI3K/AKT/mTOR pathway and epithelial-mesenchymal transition (EMT) markers was analyzed by Western blotting.

Main Results:

  • Parishin A significantly inhibited OSCC cell viability, colony formation, migration, and invasion in a dose-dependent manner, without affecting normal cells.
  • Parishin A treatment led to increased E-cadherin and decreased N-cadherin and vimentin, indicating inhibition of EMT.
  • The compound reduced phosphorylation of PI3K, AKT, and mTOR, suggesting modulation of this critical signaling pathway.

Conclusions:

  • Parishin A demonstrates potent anti-cancer activity against OSCC.
  • These findings suggest Parishin A holds promise as a potential therapeutic agent for oral squamous cell carcinoma.
Keywords:
EMTPI3K/AKT/mTOR pathwayoral squamous cell carcinomaparishin Aproliferation

More Related Videos

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells08:54

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

Published on: July 20, 2014

14.0K
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

348

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K